Renibus co-CEOs Frank Stonebanks (L) and Jeff Keyser
Exclusive: Texas biotech raises $47M to move heart surgery drug into pivotal study
Renibus means kidney in Latin, but Renibus Therapeutics is going for the heart first.
The Southlake, TX-based biotech raised a $47 million Series B to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
